Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
G. Chen(Harbin Medical University), Changxuan You(Southern Medical University), C. Wang(Tianjin Medical University Cancer Institute and Hospital), Shengxiang Ren(Tongji University), Lin Chen(Shantou University), Sheng Lu(Shanghai Jiao Tong University), J. Wang(Peking University), Y. Zhang(Zhejiang Cancer Hospital), Yi Luo(Guangzhou University of Chinese Medicine), M. Ye(Shanghai Jiao Tong University), Chengping Hu(Xiangya Hospital Central South University), L. Zhang(Sun Yat-sen University), W. F. Mader(Harbin Institute of Petroleum), Yi‐Long Wu(Guangdong General Hospital), Jianan Huang(First Affiliated Hospital of Soochow University), Songwen Zhou(Tongji University), S. Zhang(Capital Medical University), J. Feng(Hangzhou First People's Hospital), Xuetong Liu(Academy of Military Medical Sciences), Caicun Zhou(Shanghai Pulmonary Hospital), Qingyu Xiu(Shanghai Changzheng Hospital), L. Zhang(University of Manchester)
Cited by 120
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k